Progyny (NASDAQ:PGNY) EVP Allison Swartz Sells 2,199 Shares

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 2,199 shares of Progyny stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $17.27, for a total value of $37,976.73. Following the sale, the executive vice president directly owned 97,378 shares in the company, valued at $1,681,718.06. This trade represents a 2.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Allison Swartz also recently made the following trade(s):

• On Tuesday, March 3rd, Allison Swartz sold 4,657 shares of Progyny stock. The stock was sold at an average price of $17.40, for a total value of $81,031.80.
• On Thursday, December 4th, Allison Swartz sold 530 shares of Progyny stock. The shares were sold at an average price of $24.59, for a total transaction of $13,032.70.

Progyny Price Performance

Shares of PGNY stock traded up $0.27 during mid-day trading on Wednesday, hitting $17.79. The company had a trading volume of 2,389,172 shares, compared to its average volume of 1,591,542. The stock’s 50 day moving average price is $23.56 and its 200-day moving average price is $23.04. Progyny, Inc. has a 52-week low of $16.75 and a 52-week high of $28.75. The company has a market capitalization of $1.46 billion, a P/E ratio of 27.37, a P/E/G ratio of 1.20 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The company had revenue of $318.40 million for the quarter, compared to the consensus estimate of $314.26 million. Progyny had a net margin of 4.54% and a return on equity of 11.37%. Progyny’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.42 EPS. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, equities research analysts expect that Progyny, Inc. will post 0.6 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP lifted its holdings in Progyny by 260.9% during the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after buying an additional 1,621,688 shares in the last quarter. Loomis Sayles & Co. L P purchased a new position in Progyny during the 4th quarter worth $19,917,000. Barclays PLC raised its position in Progyny by 79.2% during the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after purchasing an additional 696,447 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Progyny by 37.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after buying an additional 545,431 shares during the period. Finally, Jupiter Asset Management Ltd. bought a new position in shares of Progyny during the 2nd quarter worth $10,525,000. 94.93% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PGNY has been the subject of a number of research reports. Citigroup raised Progyny to an “outperform” rating in a research note on Tuesday, January 20th. Zacks Research cut Progyny from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a research report on Monday, December 29th. Citizens Jmp raised Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price objective on the stock in a research note on Tuesday, January 20th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Progyny in a research note on Wednesday, January 21st. Eight investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Progyny presently has an average rating of “Moderate Buy” and a consensus target price of $28.80.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.